These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 6116593)
21. Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats. Fuller RW; Perry KW Biochem Pharmacol; 1982 Jun; 31(12):2199-200. PubMed ID: 7115441 [No Abstract] [Full Text] [Related]
22. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Jähnichen S; Horowski R; Pertz HH Eur J Pharmacol; 2005 Apr; 513(3):225-8. PubMed ID: 15862804 [TBL] [Abstract][Full Text] [Related]
23. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Seeman P Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435 [TBL] [Abstract][Full Text] [Related]
24. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. Claustre Y; Fage D; Zivkovic B; Scatton B J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197 [TBL] [Abstract][Full Text] [Related]
25. The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent. Koller WC; Weiner WJ; Diamond BI; Nausieda PA; Klawans HL Neuropharmacology; 1980 Sep; 19(9):831-7. PubMed ID: 7191490 [No Abstract] [Full Text] [Related]
26. Effect of fluoxetine and metergoline on amphetamine-induced rise in plasma corticosterone. Knych ET; Eisenberg RM Life Sci; 1980 May; 26(18):1489-96. PubMed ID: 6967139 [No Abstract] [Full Text] [Related]
27. Effects of specific D-1 and D-2 dopamine agonists (LY141865 and SKF-38393) and pergolide on urinary output of rats. Leander JD Arch Int Pharmacodyn Ther; 1987 Oct; 289(2):290-5. PubMed ID: 2962555 [TBL] [Abstract][Full Text] [Related]
29. Characterization of the neurogenic vasodilatation elicited by central dopamine receptor stimulation with pergolide. Lokhandwala MF; Kivlighn SD; Jandhyala BS J Pharmacol Exp Ther; 1984 Mar; 228(3):696-703. PubMed ID: 6707919 [TBL] [Abstract][Full Text] [Related]
30. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist. Foreman MM; Fuller RW; Hynes MD; Gidda JS; Nichols CL; Schaus JM; Kornfeld EC; Clemens JA J Pharmacol Exp Ther; 1989 Jul; 250(1):227-35. PubMed ID: 2526214 [TBL] [Abstract][Full Text] [Related]
31. Effect of ergovaline, loline, and dopamine antagonists on rat pituitary cell prolactin release in vitro. Strickland JR; Cross DL; Birrenkott GP; Grimes LW Am J Vet Res; 1994 May; 55(5):716-21. PubMed ID: 8067623 [TBL] [Abstract][Full Text] [Related]
32. Role of dopamine receptors in gastrointestinal motility. Dhasmana KM; Banerjee AK; Zhu YN; Erdmann W; Parmar SS; Salzman SK Res Commun Chem Pathol Pharmacol; 1989 Jun; 64(3):485-8. PubMed ID: 2571179 [TBL] [Abstract][Full Text] [Related]
33. Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinaemic women. L'Hermite M; Debusschere P Acta Endocrinol (Copenh); 1982 Dec; 101(4):481-3. PubMed ID: 7158225 [TBL] [Abstract][Full Text] [Related]
34. Dopamine receptor modulation of corticosterone secretion in neonatal and adult rats. Kitchen I; Kelly M; Turner M J Pharm Pharmacol; 1988 Aug; 40(8):580-1. PubMed ID: 2907016 [TBL] [Abstract][Full Text] [Related]
35. Effects of phencyclidine on the release of radioactivity from rat striatal slices labeled with [3H]choline. Leventer SM; Johnson KM J Pharmacol Exp Ther; 1983 May; 225(2):332-6. PubMed ID: 6842397 [TBL] [Abstract][Full Text] [Related]
36. Dopamine antagonists induce gastric lesions in rats. Sikirić P; Geber J; Ivanović D; Suchanek E; Gjuris V; Tućan-Foretić M; Mise S; Cvitanović B; Rotkvić I Eur J Pharmacol; 1986 Nov; 131(1):105-9. PubMed ID: 3816940 [TBL] [Abstract][Full Text] [Related]
37. Pergolide mesylate: its effects on circulating anterior pituitary hormones in man. Perryman RL; Rogol AD; Kaiser DL; MacLeod RM; Thorner MO J Clin Endocrinol Metab; 1981 Oct; 53(4):772-8. PubMed ID: 6793609 [TBL] [Abstract][Full Text] [Related]
38. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067. Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993 [TBL] [Abstract][Full Text] [Related]
39. The effect of mesulergine on prolactin secretion and anterior pituitary cells morphology in diethylstilboestrol-treated female Wistar rats. Pisarek H; Stepien H Histol Histopathol; 1992 Jan; 7(1):111-7. PubMed ID: 1576426 [TBL] [Abstract][Full Text] [Related]